SwePub
Sök i SwePub databas

  Utökad sökning

Träfflista för sökning "WFRF:(Dickstein K) "

Sökning: WFRF:(Dickstein K)

  • Resultat 1-10 av 77
  • [1]234567...8Nästa
Sortera/gruppera träfflistan
   
NumreringReferensOmslagsbildHitta
1.
  •  
2.
  •  
3.
  •  
4.
  •  
5.
  •  
6.
  • Gustafsson, I, et al. (författare)
  • Metabolic control by means of insulin in patients with type 2 diabetes and acute myocardial infarction (DIGAMI 2) : effects on mortality and morbidity--secondary publication
  • 2006
  • Ingår i: Ugeskrift for læger. - : Almindelige danske Lægeforening. - 0041-5782 .- 1603-6824. ; 168:6, s. 581-584
  • Tidskriftsartikel (refereegranskat)abstract
    • Patients with diabetes have an unfavourable prognosis after an acute myocardial infarction. The DIGAMI 2 study investigated the effect of various metabolic treatment strategies in type 2 diabetic patients with acute myocardial infarction: acutely introduced, long-term insulin treatment did not improve survival when compared with conventional management at similar levels of glucose control. However, good glucose control seems important since the glucose level was found to be a strong predictor of long-term mortality in this patient category.
  •  
7.
  •  
8.
  •  
9.
  •  
10.
  • O'Connor, C. M., et al. (författare)
  • Effect of nesiritide in patients with acute decompensated heart failure
  • 2011
  • Ingår i: The New England journal of medicine. - : Massachusetts Medical Society. - 0028-4793 .- 1533-4406. ; 365:1, s. 32-43
  • Tidskriftsartikel (refereegranskat)abstract
    • BACKGROUND: Nesiritide is approved in the United States for early relief of dyspnea in patients with acute heart failure. Previous meta-analyses have raised questions regarding renal toxicity and the mortality associated with this agent. METHODS: We randomly assigned 7141 patients who were hospitalized with acute heart failure to receive either nesiritide or placebo for 24 to 168 hours in addition to standard care. Coprimary end points were the change in dyspnea at 6 and 24 hours, as measured on a 7-point Likert scale, and the composite end point of rehospitalization for heart failure or death within 30 days. RESULTS: Patients randomly assigned to nesiritide, as compared with those assigned to placebo, more frequently reported markedly or moderately improved dyspnea at 6 hours (44.5% vs. 42.1%, P=0.03) and 24 hours (68.2% vs. 66.1%, P=0.007), but the prespecified level for significance (P
  •  
Skapa referenser, mejla, bekava och länka
  • Resultat 1-10 av 77
  • [1]234567...8Nästa
 
pil uppåt Stäng

Kopiera och spara länken för att återkomma till aktuell vy